Investigating how ETS1 influences survival in a type of leukemia called T-ALL
Defining the genetic mechanisms of ETS1 dependency in Notch-activated T Cell Acute Lymphoblastic Leukemia (T-ALL)
This study is looking at how a protein called ETS1 affects T cell acute lymphoblastic leukemia (T-ALL) and hopes to find a way to make T-ALL cells less able to survive, which could lead to better treatments with fewer side effects for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10995385 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the ETS1 transcription factor in T cell acute lymphoblastic leukemia (T-ALL), a cancer that often involves mutations in the NOTCH1 signaling pathway. The study aims to explore how inhibiting ETS1 can impair the survival of T-ALL cells while potentially causing fewer side effects compared to traditional Notch inhibitors. By identifying specific genetic elements that ETS1 regulates, the research seeks to uncover new therapeutic targets that could improve treatment outcomes for patients with T-ALL.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with T cell acute lymphoblastic leukemia, particularly those with mutations in the NOTCH1 pathway.
Not a fit: Patients with other types of leukemia or those without NOTCH1 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with T-ALL.
How similar studies have performed: Previous research has shown promise in targeting ETS1 for leukemia treatment, suggesting that this approach could be a viable option.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Lin, Karena Hsijan — University of Michigan at Ann Arbor
- Study coordinator: Lin, Karena Hsijan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.